SCHEMBL3391163

SCHEMBL3391163

CC1CCC(=O)CC1S(=O)(=O)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
ACHE P22303 1/20 0.38
ALDH1A1 P00352 4/20 0.38
POLB P06746 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PSIP1 O75475 1/20 0.36
MMP3 P08254 1/20 0.35
MMP8 P22894 1/20 0.35
AKR1C3 P42330 1/20 0.35
PARL Q9H300 2/20 0.35
HTR2A P28223 2/20 0.35
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
HTR2C P28335 1/20 0.33
KCNH2 Q12809 1/20 0.33
MMP2 P08253 1/20 0.33
ANPEP P15144 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13900254 1.00 MAPT (0.44) MAPTACHEALDH1A1POLBL3MBTL1
SCHEMBL15944148 0.78 MAPT (0.42) MAPTALDH1A1MMP3MMP8AKR1C3
SCHEMBL14821016 0.78 MAPT (0.42) MAPTALDH1A1MMP3MMP8AKR1C3
SCHEMBL15940394 0.78 MAPT (0.42) MAPTALDH1A1MMP3MMP8AKR1C3
SCHEMBL14821447 0.78 MAPT (0.42) MAPTALDH1A1MMP3MMP8AKR1C3
SCHEMBL27721305 0.76 MAPT (0.49) MAPTACHEALDH1A1L3MBTL1PSIP1
SCHEMBL13909336 0.76 MAPT (0.35) MAPTALDH1A1MMP3MMP8AKR1C3
SCHEMBL23720121 0.75 L3MBTL1 (0.46) MAPTACHEALDH1A1L3MBTL1PSIP1
SCHEMBL3392609 0.71 MAPT (0.55) MAPTACHEALDH1A1POLBL3MBTL1
SCHEMBL3387151 0.70 MAPT (0.50) MAPTACHEALDH1A1POLBMMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1839653-B9 THERAPEUTIC AGENT FOR SENSORY DISORDERS MEIJI DAIRIES CORP (JP) 2010-12-22 EP disclosed
EP-1368013-B1 CYCLOHEXENONE DERIVATIVE FOR TREATING DIABETIC NEUROPATHY MEIJI DAIRIES CORP (JP) 2010-12-22 EP disclosed
US-7838565-B2 Use of cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications MEIJI DAIRIES CORPORATION (JP) 2010-11-23 US disclosed
EP-2196200-A1 Cyclohexenone derivative for treating or preventing hypesthesia or hyperesthesia caused by diabetes Meiji Dairies Corporation (JP) 2010-06-16 EP disclosed
EP-1839653-B1 THERAPEUTIC AGENT FOR SENSORY DISORDERS MEIJI DAIRIES CORP (JP) 2010-06-09 EP disclosed
EP-1322748-B1 STEM CELL DIFFERENTIATION-INDUCING PROMOTER MEIJI DAIRIES CORP (JP) 2009-12-02 EP disclosed
US-20090069442-A1 Therapeutic Agent for Sensory Abnormality MEIJI CO., LTD (JP) 2009-03-12 US disclosed
US-20080312336-A1 Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder UNIVERSITE DE STRASBOURG (FR) 2008-12-18 US disclosed
EP-1839653-A1 THERAPEUTIC AGENT FOR SENSORY ABNORMALITY Meiji Dairies Corporation (JP) 2007-10-03 EP disclosed
US-7166642-B1 Use of cyclohexenone long-chain alcohol for treating neurodegenerative diseases MEIJI DAIRIES CORPORATION (JP) 2007-01-23 US disclosed
EP-1322748-A2 STEM CELL DIFFERENTIATION-INDUCING PROMOTER Meiji Dairies Corporation (JP) 2003-07-02 EP disclosed
EP-1003706-B1 CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME MEIJI MILK PROD CO LTD (JP) 2003-03-05 EP disclosed
WO-2002066023-A1 USE OF A CYCLOHEXENONE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DIABETIC COMPLICATIONS MEIJI DAIRIES CORPORATION (JP) 2002-08-29 WO disclosed
WO-2002066024-A1 USE OF CYCLOHEXENONE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF DYSURIA MEIJI DAIRIES CORPORATION (JP) 2002-08-29 WO disclosed
WO-2002029014-A2 STEM CELL DIFFERENTIATION-INDUCING PROMOTER MEIJI DAIRIES CORPORATION (JP) 2002-04-11 WO disclosed
EP-1150667-A1 CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS Meiji Dairies Corporation (JP) 2001-11-07 EP disclosed
US-6228893-B1 TREATING DEMENTIA MEIJI MILK PRODUCTS CO., LTD. (JP) 2001-05-08 US disclosed
WO-2000047199-A1 USE OF A CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING NEURODEGENERATIVE DISEASES MEIJI DAIRIES CORPORATION (JP) 2000-08-17 WO disclosed
EP-1003706-A1 CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME MEIJI MILK PRODUCTS COMPANY LIMITED (JP) 2000-05-31 EP disclosed
WO-1999008987-A1 CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME MEIJI MILK PRODUCTS CO., LTD. (JP) 1999-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312336-A1 Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder CPT1B, CHRM1, ADRA1D MAPT 4599/4885ACHE 3586/4885ALDH1A1 416/4885
US-20090069442-A1 Therapeutic Agent for Sensory Abnormality PMP22, NGF, HRH1 MAPT 3594/4885ACHE 651/4885ALDH1A1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.